Table 2 |
|||||||
|
Interpahse FISH results of the patients with the TEL-AML1 fusion after complete remission as MRD |
|||||||
|
Clinical course |
|||||||
|
|
|||||||
|
CR1 |
CR2 |
CR2, CNS relapse and death |
Resistant and death |
Total |
P |
||
|
|
|||||||
|
t (12; 21) at Remission (MRD) |
Yes |
12 |
2 |
1 |
- |
15 |
0.01 |
|
|
|||||||
|
No |
6 |
9 |
- |
- |
15 |
||
|
|
|||||||
|
Total |
18 |
11 |
1 |
- |
30 |
||
|
|
|||||||
|
FISH was performed to the patients with a positive t(12;21) at the time of diagnosis who passed to remission; a total number of 30 patients. FISH, fluorescence in situ hybridization; CR1, first complete remission; CR2, second complete remission; CNS, involvement of the central nervous system |
|||||||
|
Mosad et al. Journal of Hematology & Oncology 2008 1:17 doi:10.1186/1756-8722-1-17 |
|||||||
